A randomized controlled trial to evaluate the slow acting symptom modifying effect of colchicine in patients with osteoarthritis of the knee

Investigator0 个研究点目标入组 81 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•1. American college of rheumatology (ACR) criteria and radiographic Kellgren & Lawrence criteria for osteoarthritis;
•2. Knee osteoarthritis;
•3. Non existence of Calcium pyrophosphate dihydrate crystal deposition disease (CPPD) arthritis in other joints;
•4. No History of gout and pseudo-gout;
•5. No History of inflammatory diseases according to laboratory;
•6. Non existence of liver, kidney, cardiovascular diseases, cardiomyopathy, moderate to severe neouropathy, GI problems, fibromyalgia, infection;
•7. No History of knee joint replacement;
•8. No concurrent use of drug interfering with colchicine;
•9. No existence of these laboratory tests:
•White blood cells <3500/mm3
•Hemoglobin <10 mg/dl
•Creatinine >1.3 mg/dl
•Amino transferase >45 IU
•uric acid >6.5 mg/dl
•10. At least 2 months after intra-articular corticosteroids and 3 months after intra-articular hyaluronic acid;
•11. Using 2 weeks naproxen;
•12. At least 4-6 months after use of glucoseamine, chondroitine sulfate or methylsulfonylmethane (MSM);
•13. No contra-indication of colchicine;
•14. Co-operation.
•Exclusion criteria:
•1. No use of drugs according to the study protocol;
•2. Severe side effect of colchicine or placebo;
•3. Aggravation of knee pain;
•4. Using analgesics due to other problems;
•5. Knee trauma or any other problems interfering with drug use in knee osteoarthritis;
•6. Loss of follow-up.

发起方

Investigator